(UroToday.com) The field of advanced prostate cancer has rapidly progressed over the past 15 years. Prior to the publication of TAX-327, there were no proven life-prolonging therapies for patients with metastatic castration-resistant prostate cancer (mCRPC). Since that time, there have been many new agents that have proven survival benefits including taxane-based chemotherapy, agents targeting the androgen axis, and bone-targeting agents. Most recently, there has been interested in developing targeted therapies. Among patients with homologous recombination repair (HRR) mutations, the use of poly (ADP-ribose) polymerase (PARP) inhibitors (including olaparib and rucaparib) has proven benefit. However, despite all these advances, mCRPC remains an uncurable disease state and there is room for further benefit.